Search Results - "Leppä, S"

Intravenous but not intrathecal central nervous system–directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma by Mannisto, S., Vähämurto, P., Pollari, M., Clausen, M.R., Jyrkkiö, S., Kellokumpu-Lehtinen, P.-L., Kovanen, P., Karjalainen-Lindsberg, M.-L., d’Amore, F., Leppä, S.

“…Testicular lymphoma is a rare malignancy affecting mainly elderly men, the majority representing diffuse large B-cell lymphoma (DLBCL). Its relapse rate is…”
Get full text

TOBACCO SMOKING IMPAIRS SURVIVAL IN LYMPHOMA PATIENTS IN TWO FINNISH POPULATION‐BASED COHORTS by Reunamo, T., Mikkola, T., Laitinen, T., Bärlund, M., Österlund, P., Alanne, E., Jyrkkiö, S., Leppä, S., Minn, H., Heervä, E.

Get full text

Enhanced ctDNA Profiling Reveals Molecular Determinants of Response and Resistance in Relapsed and Refractory Mantle Cell Lymphoma (NLG‐MCL7‐VALERIA) by Meriranta, L., Kolstad, A., Hutchings, M., Pasanen, A., Niemann, C. Utoft, Riise, J., Christensen, J. Haaber, Wader, K. Fahl, Glimelius, I., Leppä, S., Jerkeman, M.

Get full text

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma by Leivonen, S-K, Taskinen, M, Cervera, A, Karjalainen-Lindsberg, M-L, Delabie, J, Holte, H, Lehtonen, R, Hautaniemi, S, Leppä, S

“…Effect of alternative splicing (AS) on diffuse large B-cell lymphoma (DLBCL) pathogenesis and survival has not been systematically addressed. Here, we compared…”
Get full text

CHARACTERIZATION OF CANCER ASSOCIATED FIBROBLASTS IN CLASSICAL HODGKIN LYMPHOMA by Karihtala, K., Leivonen, S.‐K., Karjalainen‐Lindsberg, M.‐L., Östman, A., Pellinen, T., Leppä, S.

Get full text

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY by Dickinson, M., Carlo‐Stella, C., Morschhauser, F., Falchi, L., Bachy, E., Cartron, G., Khan, C., Tani, M., Martinez‐Lopez, J., Bartlett, N., Salar, A., Brody, J., Leppä, S., Mulvihill, E., Lundberg, L., Relf, J., Xie, Y., Bottos, A., Humphrey, K., Hutchings, M.

Get full text

Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1 by Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Özcan, M., Kosinova, M., Provencio, M., Magagnoli, M., Bouabdallah, K., Heo, D. S., Diong, C. P., Munoz, J., Cao, A., Hiemeyer, F., Odongo, F., Garcia‐Vargas, J., Childs, B. H., Zinzani, P. L.

Get full text

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by Madsen, C., Clausen, M.R., Plesner, T.L., Pasanen, A., Kuismanen, T., Bentzen, H.H., Jørgensen, J.M., Sillesen, I.B., Himmelstrup, B.M., Rønnov-Jessen, D., Jensen, K.R., Pettinger, A.M., Ludvigsen, M., Leppä, S., d'Amore, F.A.

“…The introduction of the anti-CD20 antibody rituximab in combination with chemotherapy (R-chemo) has improved the prognosis of patients with follicular lymphoma…”
Get full text

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE by Belada, D., Leppä, S., Wahlin, B. E., Nijland, M., Christensen, J. H., Vos, S., Holte, H., Linton, K. M., Abbas, A., Wang, L., Dinh, M., Elliott, B., Falchi, L.

Get full text

CLINICAL SIGNIFICANCE OF T‐CELL EXHAUSTION IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA by Leppä, S., Autio, M., Brück, O., Mustjoki, S., Jørgensen, J., Karjalainen‐Lindsberg, M., Beiske, K., Holte, H., Pellinen, T., Leivonen, S.

Get full text

YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDING BCL‐2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE‐DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS by Leppä, S., Jørgensen, J., Tierens, A., Meriranta, L., Østlie, I., Brown, P., Fagerli, U., Larsen, T.S., Mannisto, S., Munksgaard, L., Maisenhølder, M., Vasala, K., Meyer, P., Jerkeman, M., Björkholm, M., Fluge, Ø., Jyrkkiö, S., Ralfkiaer, E., Spetalen, S., Karjalainen‐Lindsberg, M., Holte, H.

Get full text

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB by Dreyling, M., Santoro, A., Leppä, S., Demeter, J., Follows, G.A., Lenz, G., Kim, W.S., Mollica, L., Nagler, A., Phipps Diong, C., Provencio, M., Magagnoli, M., Munoz, J., Hiemeyer, F., Liu, L., Miriyala, A., Rodrigues, L., Garcia‐Vargas, J., Childs, B.H., Zinzani, P.L.

Get full text

SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS‐1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA by Zinzani, P.L., Santoro, A., Leppä, S., Demeter, J., Follows, G.A., Lenz, G., Kim, W.S., Mollica, L., Nagler, A., Phipps Diong, C., Provencio, M., Magagnoli, M., Munoz, J., Miriyala, A., Liu, L., Zhang, M., Garcia‐Vargas, J., Childs, B.H., Dreyling, M.

Get full text

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS by Belada, D., Falchi, L., Leppä, S., Vermaat, J. S., Holte, H., Hutchings, M., Lugtenburg, P., de Vos, S., Abrisqueta, P., Nijland, M., Merryman, R. W., Christensen, J. H., Wahlin, B. E., Linton, K. M., Wang, L., Abbas, A., Rana, A., Quadri, S., Sureda, A.

Get full text

ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma - the Nordic Lymphoma Group experience by Jerkeman, M, Leppä, S, Kvaløy, S, Holte, H

“…:  Objective: To evaluate ICE (ifosfamide, carboplatin, etoposide) as second‐line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms…”
Get full text

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma by Meriranta, Leo, Alkodsi, Amjad, Pasanen, Annika, Lepistö, Maija, Mapar, Parisa, Blaker, Yngvild Nuvin, Jørgensen, Judit, Karjalainen-Lindsberg, Marja-Liisa, Fiskvik, Idun, Mikalsen, Lars Tore G., Autio, Matias, Björkholm, Magnus, Jerkeman, Mats, Fluge, Øystein, Brown, Peter, Jyrkkiö, Sirkku, Holte, Harald, Pitkänen, Esa, Ellonen, Pekka, Leppä, Sirpa

“…Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-cell lymphoma (DLBCL) is a clinical challenge hampering the…”
Get full text

Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1482 patients transplanted in 1990-2003 by Jantunen, E., Itälä, M., Siitonen, T., Koivunen, E., Leppä, S., Juvonen, E., Kuittinen, O., Lehtinen, T., Koistinen, P., Nyman, H., Nousiainen, T., Volin, L., Remes, K.

“…: Introduction:  Data on the incidence and causes of late (>100 d) non‐relapse mortality (NRM) in autologous stem cell transplant (ASCT) recipients is limited…”
Get full text

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study by Holte, H., Leppä, S., Björkholm, M., Fluge, Ø., Jyrkkiö, S., Delabie, J., Sundström, C., Karjalainen-Lindsberg, M.-L., Erlanson, M., Kolstad, A., Fosså, A., Østenstad, B., Löfvenberg, E., Nordström, M., Janes, R., Pedersen, L.M., Anderson, H., Jerkeman, M., Eriksson, M.

“…Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized…”
Get full text

Efficacy and safety of glycosphingolipid SSEA-4 targeting CAR-T cells in an ovarian carcinoma model by Monzo, Hector J, Kalander, Kerttu, Hyytiäinen, Marko M, Elbasani, Endrit, Wall, Johanna, Moyano-Galceran, Lidia, Tanjore Ramanathan, Jayendrakishore, Jukonen, Joonas J J, Laakkonen, Pirjo, Ristimäki, Ari, Carlson, Joseph W, Lehti, Kaisa, Salehi, Sahar, Puolakkainen, Pauli, Haglund, Caj, Seppänen, Hanna, Leppä, Sirpa, Ojala, Päivi M

“…Chimeric antigen receptor (CAR) T-cell immunotherapies for solid tumors face critical challenges such as heterogeneous antigen expression. We characterized…”
Get full text

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy by Nyman, Heidi, Adde, Magdalena, Karjalainen-Lindsberg, Marja-Liisa, Taskinen, Minna, Berglund, Mattias, Amini, Rose-Marie, Blomqvist, Carl, Enblad, Gunilla, Leppä, Sirpa

“…Germinal center (GC) and non-GC phenotypes are predictors of outcome in diffuse large B-cell lymphoma (DLBCL) and can be used to stratify chemotherapy-treated…”
Get full text